

AMENDMENTS TO THE CLAIMS

1-57. (Cancelled)

58. (Previously Presented) A method for delivering a glycosaminoglycan to a subject, comprising, administering to a pulmonary tissue of a subject an unformulated dry glycosaminoglycan having a mean diameter of 1-500 microns.

59-115. (Cancelled)

116. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 1-200 microns.

117. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 1-53 microns.

118. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 1-5 microns.

119. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 5-53 microns.

120. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 53-106 microns.

121. (Previously Presented) The method of claim 58, wherein the glycosaminoglycan is a heparin, a heparan sulfate, a low molecular weight heparin.

122-203. (Cancelled)

204. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 10-500 microns.

205. (Canceled)

206. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 10-250 microns.

207. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 10-100 microns.

208. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 100-200 microns.

209. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 100-150 microns.

210. (Canceled)

211. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 20-53 microns.

212. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 53-75 microns.

213. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 75-106 microns.

214-222. (Canceled)

223. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 1-50 microns.

224. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 1-20 microns.

225. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 1-100 microns.

226. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 1-250 microns.

227. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 5-200 microns.

228. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 5-30 microns.

229. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a tap density of 0.01 - 0.4 g/cm³.

230. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a tap density of greater than 0.4 g/cm³.

231. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a tap density of less than 0.4 g/cm³.

232-252. (Canceled)